PL3773689T3 - Peptydy antygenowe do zapobiegania i leczenia raka - Google Patents

Peptydy antygenowe do zapobiegania i leczenia raka

Info

Publication number
PL3773689T3
PL3773689T3 PL19716176.3T PL19716176T PL3773689T3 PL 3773689 T3 PL3773689 T3 PL 3773689T3 PL 19716176 T PL19716176 T PL 19716176T PL 3773689 T3 PL3773689 T3 PL 3773689T3
Authority
PL
Poland
Prior art keywords
cancer
prevention
treatment
antigenic peptides
antigenic
Prior art date
Application number
PL19716176.3T
Other languages
English (en)
Inventor
Laurent Chene
Christophe Bonny
Francesco STROZZI
Original Assignee
Enterome S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterome S.A. filed Critical Enterome S.A.
Publication of PL3773689T3 publication Critical patent/PL3773689T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19716176.3T 2018-04-11 2019-04-11 Peptydy antygenowe do zapobiegania i leczenia raka PL3773689T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305444 2018-04-11
EP2018077512 2018-10-09
PCT/EP2019/059329 WO2019197567A2 (en) 2018-04-11 2019-04-11 Antigenic peptides for prevention and treatment of cancer

Publications (1)

Publication Number Publication Date
PL3773689T3 true PL3773689T3 (pl) 2023-03-13

Family

ID=66092357

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19716176.3T PL3773689T3 (pl) 2018-04-11 2019-04-11 Peptydy antygenowe do zapobiegania i leczenia raka

Country Status (19)

Country Link
US (2) US12016910B2 (pl)
EP (2) EP4169528A1 (pl)
JP (2) JP7384819B2 (pl)
CN (2) CN112118863B (pl)
AU (1) AU2019253217B2 (pl)
BR (1) BR112020020780A2 (pl)
CA (1) CA3094262A1 (pl)
DK (1) DK3773689T5 (pl)
ES (1) ES2935702T3 (pl)
FI (1) FI3773689T3 (pl)
HR (1) HRP20230007T1 (pl)
HU (1) HUE060791T2 (pl)
LT (1) LT3773689T (pl)
MX (2) MX2020010701A (pl)
PL (1) PL3773689T3 (pl)
RS (1) RS63873B1 (pl)
SI (1) SI3773689T1 (pl)
SM (1) SMT202300021T1 (pl)
WO (1) WO2019197567A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
CN110022893B (zh) 2016-10-07 2023-12-29 恩特罗姆公司 用于癌症疗法的免疫原性化合物
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
US20230105457A1 (en) * 2019-10-16 2023-04-06 Enterome S.A. Immunogenic Compounds For Treatment Of Adrenal Cancer
EP4357356A3 (en) * 2019-11-15 2024-07-31 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy
CN111197040B (zh) * 2020-01-21 2023-08-08 福建亿彤生物科技有限公司 壳多糖酶3样蛋白1（chi3l1）抗原表位肽、抗原、抗体、用途及试剂盒
CN114163511B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
CA3246416A1 (en) * 2022-03-31 2023-10-05 Enterome S.A. Antigenic Peptides for Cancer Prevention and Treatment
IT202200006785A1 (it) * 2022-04-06 2023-10-06 Istituto Naz Tumori Irccs Fondazione G Pascale Analoghi di antigeni tumorali da microbiota e usi relativi
KR20240017325A (ko) * 2022-07-29 2024-02-07 주식회사 엘지화학 항원 전달용 재조합 융합 단백질 및 이의 이용

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO2001000225A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
BR0009166A (pt) 1999-03-19 2001-12-26 Smithkline Beecham Biolog Vacina
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2001062776A1 (en) 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
WO2003092717A1 (en) 2002-03-22 2003-11-13 The Penn State Research Foundation Cancer immunotherapy
AU2003291632A1 (en) 2002-10-03 2004-04-23 Epimmune Inc Hla binding peptides and their uses
CA2558733C (en) 2004-02-06 2016-04-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
EP2089057A2 (en) 2006-12-11 2009-08-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
CN104774261B (zh) * 2007-08-20 2018-03-06 肿瘤疗法科学股份有限公司 Foxm1 肽和包含foxm1 肽的药剂
NO2119726T3 (pl) 2008-05-14 2015-05-23
EP2324057B1 (en) 2008-08-12 2018-03-21 MSD Italia S.r.l. Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
EP2172211B1 (en) * 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
TWI469791B (zh) * 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
EP2500350B1 (en) * 2009-11-03 2018-08-15 Korea University Research And Business Foundation Composite of a protein comprising zinc oxide-bonding peptides and zinc oxide nanoparticles, and use thereof
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
EP2608799B1 (en) * 2010-08-24 2018-12-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
SMT202200229T1 (it) 2011-10-03 2022-07-21 Modernatx Inc Nucleosidi, nucleotidi e acidi nucleici modificati e loro usi
WO2013101690A1 (en) 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
EP2828664B1 (en) 2012-03-19 2018-09-26 Stemline Therapeutics Inc. Methods for treating and monitoring the status of cancer
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2849772A4 (en) 2012-05-16 2016-03-02 Stemline Therapeutics Inc TUMOR VACCINES TREATED AGAINST CANCER STEM CELLS
US20140141044A1 (en) 2012-11-12 2014-05-22 Dana-Farber Cancer Institute, Inc. Cord Colitis Syndrome Pathogen
KR20150093768A (ko) 2012-12-05 2015-08-18 스트라테지아 테라퓨틱스, 인코포레이티드 단백질 발현 증진 폴리펩타이드
US9764037B2 (en) 2012-12-06 2017-09-19 Victoria Link Limited Conjugate compounds
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
CA3205428A1 (en) * 2014-06-06 2015-12-10 Herlev Hospital Determining antigen recognition through barcoding of mhc multimers
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
US20180078627A1 (en) 2015-03-31 2018-03-22 Agency For Science, Technology And Research Method for antigen loading of dendritic cells and vaccine
RU2738418C2 (ru) * 2015-10-08 2020-12-14 Онкотерапи Сайенс, Инк. Пептид, полученный из foxm1, и включающая его вакцина
EP3464630A1 (en) 2016-05-23 2019-04-10 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Methods of diagnosing cancer using cancer testis antigens
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
CN110022893B (zh) 2016-10-07 2023-12-29 恩特罗姆公司 用于癌症疗法的免疫原性化合物
CN111201032B (zh) 2017-10-09 2024-05-31 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
US20230105457A1 (en) 2019-10-16 2023-04-06 Enterome S.A. Immunogenic Compounds For Treatment Of Adrenal Cancer
EP4357356A3 (en) 2019-11-15 2024-07-31 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy

Also Published As

Publication number Publication date
MX2020010701A (es) 2021-01-20
WO2019197567A2 (en) 2019-10-17
HRP20230007T1 (hr) 2023-03-03
FI3773689T3 (fi) 2023-01-31
EP3773689A2 (en) 2021-02-17
EP3773689B1 (en) 2022-11-09
US20240293520A1 (en) 2024-09-05
ES2935702T3 (es) 2023-03-09
RS63873B1 (sr) 2023-02-28
WO2019197567A3 (en) 2019-11-28
CA3094262A1 (en) 2019-10-17
DK3773689T3 (da) 2023-01-16
MX2023014457A (es) 2023-12-15
EP4169528A1 (en) 2023-04-26
JP7670445B2 (ja) 2025-04-30
US20210113678A1 (en) 2021-04-22
CN120535570A (zh) 2025-08-26
CN112118863A (zh) 2020-12-22
BR112020020780A2 (pt) 2021-03-02
JP2021520818A (ja) 2021-08-26
DK3773689T5 (da) 2024-08-19
AU2019253217A1 (en) 2020-10-15
SMT202300021T1 (it) 2023-03-17
AU2019253217B2 (en) 2025-09-25
US12016910B2 (en) 2024-06-25
SI3773689T1 (sl) 2023-02-28
HUE060791T2 (hu) 2023-04-28
JP2024016203A (ja) 2024-02-06
LT3773689T (lt) 2023-01-25
JP7384819B2 (ja) 2023-11-21
CN112118863B (zh) 2025-05-30

Similar Documents

Publication Publication Date Title
PL3773689T3 (pl) Peptydy antygenowe do zapobiegania i leczenia raka
IL255333A0 (en) Vaccines for the treatment and prevention of cancer
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
IL276808A (en) Preparations and methods for the treatment of cancer
IL279347B1 (en) Gremlin-1 antagonist for cancer prevention and treatment
SMT202400048T1 (it) Peptidi antigenici per la prevenzione e il trattamento del tumore maligno delle cellule b
SG11202011117VA (en) Treatment of cancer
IL286297A (en) Minimal residual cancer treatment methods
SG11202006160RA (en) Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
IL280468A (en) Secondary vaccine particles for cancer treatment
GB201812647D0 (en) Viral vectors and methods for the prevention or treatment of cancer
IL281782A (en) Drug combination for cancer treatment
GB201810635D0 (en) Peptides and cancer treatment
GB201820098D0 (en) Methods of cancer treatment
SG11202000724XA (en) Methods and compositions for the treatment of cancer
IL288433A (en) Peroxidase-3 activation and immunotherapy for cancer treatment
IL280262A (en) Compositions and methods for treating cancer
IL277313A (en) Sposin C Pharmaceuticals and Cancer Treatment Methods
GB201820975D0 (en) Methods of cancer treatment
PT4021487T (pt) Péptidos antigénicos para prevenir e tratar neoplasia maligna de células b
GB201815694D0 (en) Prevention and treatment of cancer
CA3290212A1 (en) Antigenic peptides for prevention and treatment of b-cell malignancy
GB201809946D0 (en) Prevention and treatment of cancer
SG11202101945PA (en) Peptide therapeutics for the treatment of cancer and uses thereof